Biotechnology, Gene-editing and Medical Research Stocks to Buy in 2019

(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.

There is nothing more powerful than a base breakout, and this had one in February of this year. This one is on a trend line right now and there is absolutely nothing wrong with the chart.

Very positive on the stock price, the company, and the partnerships they're announcing. Technicals indicate the stock may head toward 90 cents, but he says higher. Just won a contract from the Ontario government. Covid testing isn't going away. Sales should triple in the next 12 months.

Real-time, remote medical reporting from patient to care providers. Fits and starts over the years. Should be rolling up to cashflow positive. Nice runway with great growth rate. Adding new partners. Monthly subscription. Could have a bright future in next couple of years.

Doesn't know this well. They're in the cannabis sector, more in the extraction market, an area that will continue to expand. He's watching their progress in earnings.

A great spec. It's a genetic engineering company so it's bought on spec, not earnings.

On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an…

(A Top Pick May 8/17. Up 11.02%.) The period of seasonal strength for this is usually early May right through until the middle of July. We have reached the point where seasonality no longer applies. Now is a good time to take the money off the table.

(A Top Pick Oct 27/20, Up 16.7%)Stockchase Research Editor: Michael O'Reilly Our PREVIOUS TOP PICK with GILD is progressing well. To remain disciplined, we recommend trailing up the stop (from $50) to $64 at this time.

(A Top Pick Sep 24/20, Up 51.5%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend tailing up the stop (from $42) to $46.

(A Top Pick Nov 26/20, Up 32.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB has triggered its stop at $320. We recommend covering the position at this time. We will look for another entry point when value is justified again.

Stockchase Research Editor: Michael O'Reilly We reiterate BMY, a $139 billion marketcap pharma player, as a TOP PICK. The recent $13 billion acquisition of a company that focuses on blood cancer treatment has gone well, but analysts have held the stock value back as the drug will lose patent protection in 2023. If you believe…

(A Top Pick Nov 06/20, Down 1%) They just announced huge inflows after they redeemed their stake in Roche. They continue to do (and will do) more tuck-in acquisitions. And yet, it's a stock that can't get any love. There's no big news in the pipeline. Strong balance sheet. Tuck-ins will continue and it's possible…

This name has been beaten up and now offers value. There is concern that markets could experience a pull-back and one way to play that is this one. It is a large entity in the healthcare space and has under-performed its space. As we push out of the pandemic we are going to see increased…

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be…

As the Fed is about to raise interest rates, buy companies that make real, concrete things. This includes pharmas. Since he started buying this in October, it's rallied. It's up 58% YTD. Last week, it held an investor day and soared 10% in one day, but then pulled back. Why he likes it? Their drug…

They've been executing badly. Sell this and buy EW-N

Top healthcare pick. Valuation is rich, though the dividend is decent. He will suggest a better stock in Top Picks.

Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows…

The company supplies hospitals with medical supplies. 90% of their products are disposable. They have been hurt from COVID as operations have been delayed and it looks that may continue. In a normalized time, they are well situated for an aging population, which should translate into double-digits earnings growth going forward.

73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’…

This is funny in terms of a long-term outlook. They have a buildings supplies business, and the hospital protection business. Whenever there is a pandemic in the works, this company takes off. It has been moving around $4 per share, and thinks it could go a fair bit higher. He would like to get $6+…